NeuroMetrix, Inc. to Partner With Omron Healthcare Co., Ltd. for Distribution of NC-stat DPNCheck in Japan

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment of diabetic peripheral neuropathy (DPN), announced that it had entered into an agreement with Omron Healthcare Co., Ltd. to be the exclusive distributor for NC-stat® DPNCheck® in Japan. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers, which may require lower extremity amputations.

Help employers find you! Check out all the jobs and post your resume.

Back to news